Pharmacology of orismilast, a potent and selective PDE4 inhibitor.
Jonathan Ian SilverbergLars Einar FrenchRichard B WarrenBruce StroberKim KjøllerMorten O A SommerPhilippe AndresJakob FeldingAnne WeissDeniz TutkunkardasTine Skak-NielsenEmma Guttman-YasskyPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Orismilast displayed selective and potent PDE4 inhibition and broad-spectrum anti-inflammatory activity in several pre-clinical models. The results of the study support clinical development of oral orismilast as a novel treatment option for CISD including psoriasis, atopic dermatitis, and hidradenitis suppurativa.